XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc

Provided By GlobeNewswire - Last update: Dec 5, 2025

EMERYVILLE, Calif., Dec. 05, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (“XOMA Royalty”) (Nasdaq: XOMA), the biotech royalty aggregator, today announced it has successfully completed its previously announced acquisition of the entire issued and to be issued share capital of Mural Oncology plc (“Mural”) (Nasdaq: MURA) (the “Acquisition”) pursuant to an Irish High Court sanctioned scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 of Ireland (the “Scheme”). Mural shareholders received $2.035 in cash per share (the “Consideration”).

Read more at globenewswire.com

XOMA ROYALTY CORP - XOMA 8 3/8 PERP

NASDAQ:XOMAO (3/11/2026, 8:00:03 PM)

25.37

-0.11 (-0.43%)


XOMA ROYALTY CORPORATION

NASDAQ:XOMA (3/11/2026, 8:00:03 PM)

After market: 27.5 +0.54 (+2%)

26.96

-0.32 (-1.17%)


XOMA ROYALTY CORP - XOMA 8 5/8 PERP

NASDAQ:XOMAP (3/11/2026, 8:00:10 PM)

25.7844

-0.1 (-0.39%)



Find more stocks in the Stock Screener

Follow ChartMill for more
Follow us on StockTwitsFollow us on InstagramFollow us on FacebookFollow us on YouTube